135,545 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Jupiter Topco LLC

Jupiter Topco LLC acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 135,545 shares of the biopharmaceutical company’s stock, valued at approximately $40,808,000.

Several other hedge funds have also recently added to or reduced their stakes in the stock. iA Global Asset Management Inc. boosted its stake in Alnylam Pharmaceuticals by 979.5% during the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock worth $7,070,000 after acquiring an additional 16,133 shares during the last quarter. SCS Capital Management LLC acquired a new stake in Alnylam Pharmaceuticals in the second quarter worth $34,784,000. Hussman Strategic Advisors Inc. bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth $2,505,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Alnylam Pharmaceuticals during the second quarter worth $50,773,000. Finally, Hsbc Holdings PLC boosted its position in shares of Alnylam Pharmaceuticals by 22.6% during the fourth quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock worth $35,675,000 after purchasing an additional 16,503 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 1.0%

Shares of ALNY stock opened at $236.56 on Friday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $197.81 and a 12-month high of $495.55. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. The firm has a fifty day moving average of $263.44 and a 200-day moving average of $294.13. The company has a market capitalization of $31.65 billion, a price-to-earnings ratio of 43.97 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating the consensus estimate of $1.63 by $0.21. The business had revenue of $1.29 billion for the quarter, compared to analysts’ expectations of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The firm’s revenue was up 66.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.51) EPS. As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ALNY has been the subject of a number of recent analyst reports. Truist Financial lowered their price objective on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating for the company in a research report on Tuesday, August 4th. Citigroup reduced their target price on Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating on the stock in a report on Monday, August 3rd. Needham & Company LLC decreased their target price on Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Stifel Nicolaus lowered their price target on Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a report on Friday, July 31st. Finally, Raymond James Financial raised Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price target on the stock in a research report on Monday, August 3rd. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $386.14.

Insider Activity

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the sale, the director owned 1,582 shares of the company’s stock, valued at $473,302.76. This trade represents a 70.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.